Skip to main content
Log in

Drug and dietary interactions of warfarin and novel oral anticoagulants: an update

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

Abstract

Clinicians and patients around the world have been intrigued by the concept of developing an oral anticoagulant with a broad therapeutic window and few drug and dietary interactions that can be administered at fixed doses with no or minimal monitoring. The recently approved oral direct thrombin inhibitor dabigatran, along with the emerging oral anti-factor Xa inhibitors, rivaroxaban, apixaban, and edoxaban, have been developed to address many of the shortcomings of warfarin therapy. As warfarin is associated with extensive food and drug interactions, there is also a need to consider such interactions with the new oral anticoagulants. While to date few drug and dietary interactions have been reported with the new oral anticoagulants, it is still early in their development and clinical use cycle. Pharmacokinetic and pharmacodynamic profiles will have to be closely accounted for when determining the likelihood of a potential drug interaction prior to therapy initiation. As the list of drugs and supplements that interact with warfarin is continuously expanding, and the knowledge on drug interactions with the novel oral anticoagulants is still in its infancy, clinicians need to be vigilant when initiating any of these agents or when any changes in the patient’s medication profile occur and perform a close screening for potential drug and dietary interactions. The objective of this paper is to give an update on drug and dietary interactions with warfarin and the novel oral anticoagulants, dabigatran, rivaroxaban, apixaban, and edoxaban.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Wysowski DK, Nourjah P, Swartz L (2007) Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch Intern Med 167(13):1414–1419

    PubMed  Google Scholar 

  2. Wysowski DK (2007) Surveillance of prescription drug-related mortality using death certificate data. Drug Saf 30(6):533–540

    PubMed  Google Scholar 

  3. Tadros R, Shakib S (2010) Warfarin—indications, risks and drug interactions. Aust Fam Physician 39(6):476–479

    PubMed  Google Scholar 

  4. Holbrook AM et al (2005) Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 165(10):1095–1106

    PubMed  CAS  Google Scholar 

  5. Errick JK, Keys PW (1978) Co-trimoxazole and warfarin: case report of an interaction. Am J Hosp Pharm 35(11):1399–1401

    PubMed  CAS  Google Scholar 

  6. Greenlaw CW (1979) Drug interaction between co-trimoxazole and warfarin. Am J Hosp Pharm 36(9):1155–1156

    PubMed  CAS  Google Scholar 

  7. Fredriks DA (1989) Comment: TMP/SMX—warfarin interaction. DICP 23(7–8):619–620

    PubMed  CAS  Google Scholar 

  8. Cook DE, Ponte CD (1994) Suspected trimethoprim/sulfamethoxazole-induced hypoprothrombinemia. J Fam Pract 39(6):589–591

    PubMed  CAS  Google Scholar 

  9. Chafin CC et al (2000) Hospital admission due to warfarin potentiation by TMP-SMX. Nurse Pract 25(12):73–75

    PubMed  CAS  Google Scholar 

  10. Ahmed A et al (2008) Impact of preemptive warfarin dose reduction on anticoagulation after initiation of trimethoprim-sulfamethoxazole or levofloxacin. J Thromb Thrombolysis 26(1):44–48

    PubMed  CAS  Google Scholar 

  11. Fischer HD et al (2010) Hemorrhage during warfarin therapy associated with cotrimoxazole and other urinary tract anti-infective agents: a population-based study. Arch Intern Med 170(7):617–621

    PubMed  CAS  Google Scholar 

  12. Seaton TL, Celum CL, Black DJ (1990) Possible potentiation of warfarin by fluconazole. DICP 24(12):1177–1178

    PubMed  CAS  Google Scholar 

  13. Crussell-Porter LL et al (1993) Low-dose fluconazole therapy potentiates the hypoprothrombinemic response of warfarin sodium. Arch Intern Med 153(1):102–104

    PubMed  CAS  Google Scholar 

  14. Kerr HD (1993) Case report: potentiation of warfarin by fluconazole. Am J Med Sci 305(3):164–165

    PubMed  CAS  Google Scholar 

  15. Baciewicz AM et al (1994) Fluconazole–warfarin interaction. Ann Pharmacother 28(9):1111

    PubMed  CAS  Google Scholar 

  16. Kunze KL et al (1996) Warfarin-fluconazole. I. Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: in vitro studies. Drug Metab Dispos 24(4):414–421

    PubMed  CAS  Google Scholar 

  17. Allison EJ Jr, McKinney TJ, Langenberg JN (2002) Spinal epidural haematoma as a result of warfarin/fluconazole drug interaction. Eur J Emerg Med 9(2):175–177

    PubMed  Google Scholar 

  18. Mootha VV, Schluter ML, Das A (2002) Intraocular hemorrhages due to warfarin fluconazole drug interaction in a patient with presumed Candida endophthalmitis. Arch Ophthalmol 120(1):94–95

    PubMed  Google Scholar 

  19. Turrentine MA (2006) Single-dose fluconazole for vulvovaginal candidiasis: impact on prothrombin time in women taking warfarin. Obstet Gynecol 107(2 Pt 1):310–313

    PubMed  CAS  Google Scholar 

  20. Kazmier FJ (1976) A significant interaction between metronidazole and warfarin. Mayo Clin Proc 51(12):782–784

    PubMed  CAS  Google Scholar 

  21. O’Reilly RA (1976) The stereoselective interaction of warfarin and metronidazole in man. N Engl J Med 295(7):354–357

    PubMed  Google Scholar 

  22. Yacobi A, Lai CM, Levy G (1984) Pharmacokinetic and pharmacodynamic studies of acute interaction between warfarin enantiomers and metronidazole in rats. J Pharmacol Exp Ther 231(1):72–79

    PubMed  CAS  Google Scholar 

  23. Howard-Thompson A et al (2008) Intracerebral hemorrhage secondary to a warfarin–metronidazole interaction. Am J Geriatr Pharmacother 6(1):33–36

    PubMed  CAS  Google Scholar 

  24. Long E (1983) Warfarin–miconazole interaction. Arch Intern Med 143(11):2214–2215

    PubMed  CAS  Google Scholar 

  25. Colquhoun MC et al (1987) Interaction between warfarin and miconazole oral gel. Lancet 1(8534):695–696

    PubMed  CAS  Google Scholar 

  26. Shenfield GM, Page M (1991) Potentiation of warfarin action by miconazole oral gel. Aust N Z J Med 21(6):928

    PubMed  CAS  Google Scholar 

  27. Pillans P, Woods DJ (1996) Interaction between miconazole oral gel (Daktarin) and warfarin. N Z Med J 109(1029):346

    PubMed  CAS  Google Scholar 

  28. Ariyaratnam S et al (1997) Potentiation of warfarin anticoagulant activity by miconazole oral gel. BMJ 314(7077):349

    PubMed  CAS  Google Scholar 

  29. Ezsias A, Wojnarowska F, Juniper R (1997) Topical use of miconazole antifungal oral gel on warfarinized patients: a word of caution. Dent Update 24(10):421–422

    PubMed  CAS  Google Scholar 

  30. Pemberton MN et al (1998) Derangement of warfarin anticoagulation by miconazole oral gel. Br Dent J 184(2):68–69

    PubMed  CAS  Google Scholar 

  31. Silingardi M et al (2000) Miconazole oral gel potentiates warfarin anticoagulant activity. Thromb Haemost 83(5):794–795

    PubMed  CAS  Google Scholar 

  32. Thirion DJ, Zanetti LA (2000) Potentiation of warfarin’s hypoprothrombinemic effect with miconazole vaginal suppositories. Pharmacotherapy 20(1):98–99

    PubMed  CAS  Google Scholar 

  33. Murty M (2001) Miconazole–warfarin interaction: increased INR. CMAJ 165(1): pp 81–82, 85–86

  34. Devaraj A et al (2002) Interaction between warfarin and topical miconazole cream. BMJ 325(7355):77

    PubMed  CAS  Google Scholar 

  35. Pemberton MN, Oliver RJ, Theaker ED (2004) Miconazole oral gel and drug interactions. Br Dent J 196(9):529–531

    PubMed  CAS  Google Scholar 

  36. Miki A, Ohtani H, Sawada Y (2010) Warfarin and miconazole oral gel interactions: analysis and therapy recommendations based on clinical data and a pharmacokinetic model. J Clin Pharm Ther [Epub ahead of print]

  37. Thomas JL et al (2010) Hyperprothrombinemia as a result of a possible warfarin and intravaginal miconazole interaction. South Med J 103(10):1063–1065

    PubMed  Google Scholar 

  38. Purkins L et al (2003) Voriconazole potentiates warfarin-induced prothrombin time prolongation. Br J Clin Pharmacol 56(Suppl 1):24–29

    PubMed  CAS  Google Scholar 

  39. Chock AW, Stading JA (2006) Indeterminable international normalized ratio with concurrent use of warfarin and gatifloxacin. Am J Health Syst Pharm 63(16):1539–1542

    PubMed  Google Scholar 

  40. Mathews S, Cole J, Ryono RA (2006) Anticoagulation-related outcomes in patients receiving warfarin after starting levofloxacin or gatifloxacin. Pharmacotherapy 26(10):1446–1452

    PubMed  CAS  Google Scholar 

  41. Glasheen JJ, Prochazka AV (2007) The safety of levofloxacin in patients on warfarin. Am J Med 120(4):e13 author reply e15–6

    PubMed  Google Scholar 

  42. Mercadal Orfila G et al (2009) Retrospective assessment of potential interaction between levofloxacin and warfarin. Pharm World Sci 31(2):224–229

    PubMed  CAS  Google Scholar 

  43. Vadlamudi RS, Smalligan RD, Ismail HM (2007) Interaction between warfarin and levofloxacin: case series. South Med J 100(7):720–724

    PubMed  Google Scholar 

  44. Washington C et al (2007) Ciprofloxacin prolonged-release tablets do not affect warfarin pharmacokinetics and pharmacodynamics. J Clin Pharmacol 47(10):1320–1326

    PubMed  CAS  Google Scholar 

  45. Carroll DN, Carroll DG (2008) Interactions between warfarin and three commonly prescribed fluoroquinolones. Ann Pharmacother 42(5):680–685

    PubMed  Google Scholar 

  46. Glasheen JJ, Prochazka AV (2008) Further evidence of a clinically significant levofloxacin–warfarin interaction. South Med J 101(6):660 author reply 660

    PubMed  Google Scholar 

  47. Schelleman H et al (2008) Warfarin with fluoroquinolones, sulfonamides, or azole antifungals: interactions and the risk of hospitalization for gastrointestinal bleeding. Clin Pharmacol Ther 84(5):581–588

    PubMed  CAS  Google Scholar 

  48. Zhang K, Young C, Berger J (2006) Administrative claims analysis of the relationship between warfarin use and risk of hemorrhage including drug–drug and drug–disease interactions. J Manag Care Pharm 12(8):640–648

    PubMed  Google Scholar 

  49. FDA U.S. Food and Drug Administration. MedWatch The FDA Safety Information and Adverse Event Reporting Program. Drug safety labeling changes. Zithromax (azithromycin) IV, February 2009 [cited 23 Dec 2010]; Available from: http://www.fda.gov/Safety/MedWatch/SafetyInformation/Safety-RelatedDrugLabelingChanges/ucm133120.htm

  50. Foster DR, Milan NL (1999) Potential interaction between azithromycin and warfarin. Pharmacotherapy 19(7):902–908

    PubMed  CAS  Google Scholar 

  51. Lane G (1996) Increased hypoprothrombinemic effect of warfarin possibly induced by azithromycin. Ann Pharmacother 30(7–8):884–885

    PubMed  CAS  Google Scholar 

  52. Rao KB et al (2004) Enhanced hypoprothrombinemia with warfarin due to azithromycin. Ann Pharmacother 38(6):982–985

    PubMed  Google Scholar 

  53. Shrader SP, Fermo JD, Dzikowski AL (2004) Azithromycin and warfarin interaction. Pharmacotherapy 24(7):945–949

    PubMed  Google Scholar 

  54. Woldtvedt BR et al (1998) Possible increased anticoagulation effect of warfarin induced by azithromycin. Ann Pharmacother 32(2):269–270

    PubMed  CAS  Google Scholar 

  55. Malek J et al (2010) Venous thromboembolic disease in the HIV-infected patient. Am J Emerg Med [Epub ahead of print]

  56. Liedtke MD, Rathbun RC (2010) Drug interactions with antiretrovirals and warfarin. Expert Opin Drug Saf 9(2):215–223

    PubMed  CAS  Google Scholar 

  57. Fulco PP, Zingone MM, Higginson RT (2008) Possible antiretroviral therapy–warfarin drug interaction. Pharmacotherapy 28(7):945–949

    PubMed  CAS  Google Scholar 

  58. Liedtke MD, Rathbun RC (2009) Warfarin–antiretroviral interactions. Ann Pharmacother 43(2):322–328

    PubMed  CAS  Google Scholar 

  59. Dionisio D et al (2001) Need for increased dose of warfarin in HIV patients taking nevirapine. AIDS 15(2):277–278

    PubMed  CAS  Google Scholar 

  60. von Moltke LL et al (2001) Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors. J Clin Pharmacol 41(1):85–91

    Google Scholar 

  61. Bonora S et al (2008) Drug interactions between warfarin and efavirenz or lopinavir-ritonavir in clinical treatment. Clin Infect Dis 46(1):146–147

    PubMed  Google Scholar 

  62. Gatti G et al (1998) Influence of indinavir and ritonavir on warfarin anticoagulant activity. AIDS 12(7):825–826

    PubMed  CAS  Google Scholar 

  63. Knoell KR, Young TM, Cousins ES (1998) Potential interaction involving warfarin and ritonavir. Ann Pharmacother 32(12):1299–1302

    PubMed  CAS  Google Scholar 

  64. Hughes CA, Freitas A, Miedzinski LJ (2007) Interaction between lopinavir/ritonavir and warfarin. CMAJ 177(4):357–359

    PubMed  Google Scholar 

  65. Newshan G, Tsang P (1999) Ritonavir and warfarin interaction. AIDS 13(13):1788–1789

    PubMed  CAS  Google Scholar 

  66. Darlington MR (1997) Hypoprothrombinemia during concomitant therapy with warfarin and saquinavir. Ann Pharmacother 31(5):647

    PubMed  CAS  Google Scholar 

  67. Ward S et al (2007) A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess 11(14): pp 1–160, iii–iv

    Google Scholar 

  68. Robinson JG, Booth B (2010) Statin use and lipid levels in older adults: National Health and Nutrition Examination Survey, 2001 to 2006. J Clin Lipidol 4(6):483–490

    PubMed  Google Scholar 

  69. Andrus MR (2004) Oral anticoagulant drug interactions with statins: case report of fluvastatin and review of the literature. Pharmacotherapy 24(2):285–290

    PubMed  Google Scholar 

  70. Schelleman H et al (2010) Fibrate/Statin initiation in warfarin users and gastrointestinal bleeding risk. Am J Med 123(2):151–157

    PubMed  CAS  Google Scholar 

  71. Barry M (2004) Rosuvastatin–warfarin drug interaction. Lancet 363(9405):328

    PubMed  Google Scholar 

  72. Hickmott H, Wynne H, Kamali F (2003) The effect of simvastatin co-medication on warfarin anticoagulation response and dose requirements. Thromb Haemost 89(5):949–950

    PubMed  CAS  Google Scholar 

  73. Lin JC et al (1999) The effect of converting from pravastatin to simvastatin on the pharmacodynamics of warfarin. J Clin Pharmacol 39(1):86–90

    PubMed  CAS  Google Scholar 

  74. Williams D, Feely J (2002) Pharmacokinetic–pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet 41(5):343–370

    PubMed  CAS  Google Scholar 

  75. Westergren T, Johansson P, Molden E (2007) Probable warfarin–simvastatin interaction. Ann Pharmacother 41(7):1292–1295

    PubMed  CAS  Google Scholar 

  76. Kassebaum PJ, Shaw DL, Tomich DJ (2005) Possible warfarin interaction with menthol cough drops. Ann Pharmacother 39(2):365–367

    PubMed  Google Scholar 

  77. Coderre K, Faria C, Dyer E (2010) Probable warfarin interaction with menthol cough drops. Pharmacotherapy 30(1):110

    PubMed  Google Scholar 

  78. Dresser GK et al (2002) Evaluation of peppermint oil and ascorbyl palmitate as inhibitors of cytochrome P4503A4 activity in vitro and in vivo. Clin Pharmacol Ther 72(3):247–255

    PubMed  CAS  Google Scholar 

  79. Ni H, Simile C, Hardy AM (2002) Utilization of complementary and alternative medicine by United States adults: results from the 1999 national health interview survey. Med Care 40(4):353–358

    PubMed  Google Scholar 

  80. Tindle HA et al (2005) Trends in use of complementary and alternative medicine by US adults: 1997–2002. Altern Ther Health Med 11(1):42–49

    PubMed  Google Scholar 

  81. Elmer GW et al (2007) Potential interactions between complementary/alternative products and conventional medicines in a Medicare population. Ann Pharmacother 41(10):1617–1624

    PubMed  Google Scholar 

  82. Leung VW et al (2009) Prevalence of use and the risk of adverse effects associated with complementary and alternative medicine in a cohort of patients receiving warfarin. Ann Pharmacother 43(5):875–881

    PubMed  CAS  Google Scholar 

  83. Smith L et al (2004) Co-ingestion of herbal medicines and warfarin. Br J Gen Pract 54(503):439–441

    PubMed  Google Scholar 

  84. Taylor DM et al (2006) Potential interactions between prescription drugs and complementary and alternative medicines among patients in the emergency department. Pharmacotherapy 26(5):634–640

    PubMed  Google Scholar 

  85. MHRA/CSM (2004) Interaction between warfarin and cranberry juice: new advice. Curr Probl Pharmacovig 30:10

    Google Scholar 

  86. Suvarna R, Pirmohamed M, Henderson L (2003) Possible interaction between warfarin and cranberry juice. BMJ 327(7429):1454

    PubMed  Google Scholar 

  87. Grant P (2004) Warfarin and cranberry juice: an interaction? J Heart Valve Dis 13(1):25–26

    PubMed  Google Scholar 

  88. Rindone JP, Murphy TW (2006) Warfarin–cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding. Am J Ther 13(3):283–284

    PubMed  Google Scholar 

  89. Paeng CH, Sprague M, Jackevicius CA (2007) Interaction between warfarin and cranberry juice. Clin Ther 29(8):1730–1735

    PubMed  Google Scholar 

  90. Mergenhagen KA, Sherman O (2008) Elevated International Normalized Ratio after concurrent ingestion of cranberry sauce and warfarin. Am J Health Syst Pharm 65(22):2113–2116

    PubMed  Google Scholar 

  91. Welch JM, Forster K (2007) Probable elevation in international normalized ratio from cranberry juice. J Pharm Technol 23:4

    Google Scholar 

  92. Greenblatt DJ et al (2006) Interaction of flurbiprofen with cranberry juice, grape juice, tea, and fluconazole: in vitro and clinical studies. Clin Pharmacol Ther 79(1):125–133

    PubMed  CAS  Google Scholar 

  93. Mohammed Abdul MI, Jiang X, Williams KM (2008) A randomized, double-blind trial of the interaction of warfarin with cranberry but not with garlic in healthy subjects. Br J Pharmacol 154(8):1691–1700

    PubMed  CAS  Google Scholar 

  94. Ansell J et al (2009) The absence of an interaction between warfarin and cranberry juice: a randomized, double-blind trial. J Clin Pharmacol 49(7):824–830

    PubMed  CAS  Google Scholar 

  95. Mellen CK, Ford M, Rindone JP (2010) Effect of high-dose cranberry juice on the pharmacodynamics of warfarin in patients. Br J Clin Pharmacol 70(1):139–142

    PubMed  CAS  Google Scholar 

  96. Li Z et al (2006) Cranberry does not affect prothrombin time in male subjects on warfarin. J Am Diet Assoc 106(12):2057–2061

    PubMed  CAS  Google Scholar 

  97. Zikria J, Goldman R, Ansell J (2010) Cranberry juice and warfarin: when bad publicity trumps science. Am J Med 123:384–392

    PubMed  CAS  Google Scholar 

  98. Cheng TO (2007) Green tea may inhibit warfarin. Int J Cardiol 115(2):236

    PubMed  Google Scholar 

  99. Taylor JR, Wilt VM (1999) Probable antagonism of warfarin by green tea. Ann Pharmacother 33(4):426–428

    PubMed  CAS  Google Scholar 

  100. Chan HT et al (2010) Effect of herbal consumption on clinical efficacy of warfarin therapy in patients with atrial fibrillation. Eur Heart J 31(Supplement 1):2

    Google Scholar 

  101. Booth SL et al (1995) Tea and coffee brews are not dietary sources of vitamin K-1 (phylloquinone). J Am Diet Assoc 95(1):82–83

    PubMed  CAS  Google Scholar 

  102. Shord SS, Shah K, Lukose A (2009) Drug–botanical interactions: a review of the laboratory, animal, and human data for 8 common botanicals. Integr Cancer Ther 8(3):208–227

    PubMed  CAS  Google Scholar 

  103. Connolly SJ et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361(12):1139–1151

    PubMed  CAS  Google Scholar 

  104. Stangier J (2008) Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 47(5):285–295

    PubMed  CAS  Google Scholar 

  105. Blech S et al (2008) The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 36(2):386–399

    PubMed  CAS  Google Scholar 

  106. Stangier J et al (2008) Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment. J Clin Pharmacol 48(12):1411–1419

    PubMed  CAS  Google Scholar 

  107. Stangier J et al (2010) Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 49(4):259–268

    PubMed  CAS  Google Scholar 

  108. U.S. FDA (2010) Label and approval history for PRADAXA, NDA no. 022512. 2010 [cited 20 Dec 2010]; Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022512s000lbl.pdf

  109. Stangier J et al (2005) Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol 45(5):555–563

    PubMed  CAS  Google Scholar 

  110. Stangier J et al (2008) Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet 47(1):47–59

    PubMed  CAS  Google Scholar 

  111. Stangier J et al (2007) No interaction of the oral direct thrombin inhibitor dabigatran etexilate and digoxin (Abstracts). Thromb Haemost 5(Supplement 2):P-W_672

    Google Scholar 

  112. Stangier J et al (2009) Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics. Am J Cardiovasc Drugs 9(1):59–68

    PubMed  CAS  Google Scholar 

  113. US Department of Health and Human Services. US Food and Drug Administration. Briefing Information for the March 19, 2009 Cardiovascular and Renal Drugs Advisory Committee. http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/ucm138368.htm. Accessed Jan 2011

  114. Kubitza D et al (2006) Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban—an oral, direct factor Xa inhibitor—are not affected by aspirin. J Clin Pharmacol 46(9):981–990

    PubMed  CAS  Google Scholar 

  115. Samama MM (2010) The mechanism of action of rivaroxaban—an oral, direct Factor Xa inhibitor—compared with other anticoagulants. Thromb Res [Epub ahead of print]

  116. Perzborn E et al (2011) The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor. Nat Rev Drug Discov 10(1):61–75

    PubMed  CAS  Google Scholar 

  117. Kubitza D et al (2010) Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol 70(5):703–712

    PubMed  CAS  Google Scholar 

  118. Kubitza D et al (2006) Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59–7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects. J Clin Pharmacol 46(5):549–558

    PubMed  CAS  Google Scholar 

  119. Xarelto: summary of product characteristics (2010). Bayer Schering Pharma. www.Xarelto.com

  120. Perzborn E, Fischer E, Lange U (2007) Combination rivaroxaban with acethylsalicylic acid increased antithrombotic potency without affect bleeding times in animal model. J Thromb Haemost 5(Supplement 2), Abstract P-W-639

  121. Kubitza D et al (2007) Rivaroxaban (BAY 59–7939)—an oral, direct Factor Xa inhibitor—has no clinically relevant interaction with naproxen. Br J Clin Pharmacol 63(4):469–476

    PubMed  CAS  Google Scholar 

  122. Frost C, Yu Z, Moore K (2007) Apixaban, an oral direct factor Xa inhibitor: multiple-dose safety, pharmacokinetics, and pharmacodynamics in healthy subjects. J Thromb Haemost 5(Supplement 2), Abstract P-M-664

  123. Shantsila E, Lip GY (2008) Apixaban, an oral, direct inhibitor of activated Factor Xa. Curr Opin Investig Drugs 9(9):1020–1033

    PubMed  CAS  Google Scholar 

  124. Raghavan N et al (2009) Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos 37(1):74–81

    PubMed  CAS  Google Scholar 

  125. Wang L et al (2010) In vitro assessment of metabolic drug–drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. Drug Metab Dispos 38(3):448–458

    PubMed  CAS  Google Scholar 

  126. Huang J et al (2010) Apixaban versus enoxaparin in patients with total knee arthroplasty. A meta-analysis of randomised trials. Thromb Haemost 105(2):245–253

    PubMed  Google Scholar 

  127. Lassen MR et al (2010) Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 375(9717):807–815

    PubMed  CAS  Google Scholar 

  128. Frost C (2008) Food does not affect the pharmacokinetics of apixaban, an oral factor Xa inhibitor. In: IXth World Conference on Clinical Pharmacology and Therapeutics. Quebec City, Canada, T2M061

  129. Carreiro J, Ansell J (2008) Apixaban, an oral direct Factor Xa inhibitor: awaiting the verdict. Expert Opin Investig Drugs 17(12):1937–1945

    PubMed  CAS  Google Scholar 

  130. Frost C, Lee L, Li L (2007) Apixaban does not affect the pharmacokinetics of digoxin. J Clin Pharmacol 47(9):1196, Abstract # 60

    Google Scholar 

  131. Wong PC, Jiang X (2010) Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: comparison with direct inhibitors of factor VIIa, XIa and thrombin. Thromb Haemost 104(2):302–310

    PubMed  CAS  Google Scholar 

  132. Alexander JH et al (2009) Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation 119(22):2877–2885

    PubMed  Google Scholar 

  133. Ogata K et al (2010) Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol 50(7):743–753

    PubMed  CAS  Google Scholar 

  134. Furugohri T et al (2008) DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles. J Thromb Haemost 6(9):1542–1549

    PubMed  CAS  Google Scholar 

  135. Morishima Y et al (2007) Activated prothrombin complex concentrate, recombinant factor VIII and factor IX reverse prolong clotting time induced by DU-712b, a direct factor Xa inhibitor, in human plasma. J Thromb Haemost 5(Supplement 2), Abstract P-T-639

  136. Mendell J et al (2010) Effects of food on the pharmacokinetics of edoxaban, an oral direct factor Xa inhibitor, in healthy volunteers. J Clin Pharmacol [Epub ahead of print]

  137. Hasan SA (2007) Interaction of doxycycline and warfarin: an enhanced anticoagulant effect. Cornea 26(6):742–743

    PubMed  Google Scholar 

  138. McCall KL, Scott JC, Anderson HG (2005) Retrospective evaluation of a possible interaction between warfarin and levofloxacin. Pharmacotherapy 25(1):67–73

    PubMed  CAS  Google Scholar 

  139. Arnold LM, Nissen LR, Ng TM (2005) Moxifloxacin and warfarin: additional evidence for a clinically relevant interaction. Pharmacotherapy 25(6):904–907

    PubMed  Google Scholar 

  140. Anthony M et al (2009) Warfarin interactions with substances listed in drug information compendia and in the FDA-approved label for warfarin sodium. Clin Pharmacol Ther 86(4):425–429

    PubMed  CAS  Google Scholar 

  141. Dixon DL, Williams VG (2009) Interaction between gemfibrozil and warfarin: case report and review of the literature. Pharmacotherapy 29(6):744–748

    PubMed  Google Scholar 

  142. Simonson SG et al (2005) Effect of rosuvastatin on warfarin pharmacodynamics and pharmacokinetics. J Clin Pharmacol 45(8):927–934

    PubMed  CAS  Google Scholar 

  143. Battistella M et al (2005) Risk of upper gastrointestinal hemorrhage in warfarin users treated with nonselective NSAIDs or COX-2 inhibitors. Arch Intern Med 165(2):189–192

    PubMed  CAS  Google Scholar 

  144. Yeh RF et al (2006) Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. J Acquir Immune Defic Syndr 42(1):52–60

    PubMed  CAS  Google Scholar 

  145. Glueck CJ et al (2006) Interaction of duloxetine and warfarin causing severe elevation of international normalized ratio. JAMA 295(13):1517–1518

    PubMed  CAS  Google Scholar 

  146. Kurdyak PA et al (2005) Antidepressants, warfarin, and the risk of hemorrhage. J Clin Psychopharmacol 25(6):561–564

    PubMed  CAS  Google Scholar 

  147. Yamreudeewong W et al (2009) Probable interaction between warfarin and marijuana smoking. Ann Pharmacother 43(7):1347–1353

    PubMed  Google Scholar 

  148. Uno T et al (2008) The role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazole. Ther Drug Monit 30(3):276–281

    PubMed  CAS  Google Scholar 

  149. Nakajima M et al (2010) Increased anticoagulant activity of warfarin used in combination with doxifluridine. Cancer Chemother Pharmacol 66(5):969–972

    PubMed  CAS  Google Scholar 

  150. Min KA et al (2006) Effect of oxolamine on anticoagulant effect of warfarin. Am J Health Syst Pharm 63(2):153–156

    PubMed  CAS  Google Scholar 

  151. Nutescu EA et al (2006) Warfarin and its interactions with foods, herbs and other dietary supplements. Expert Opin Drug Saf 5(3):433–451

    PubMed  CAS  Google Scholar 

  152. Rupprecht HJ, Blank R (2010) Clinical pharmacology of direct and indirect factor Xa inhibitors. Drugs 70(16):2153–2170

    PubMed  CAS  Google Scholar 

  153. Ufer M (2010) Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development. Thromb Haemost 103(3):572–585

    PubMed  CAS  Google Scholar 

  154. Wittkowsky AK (2010) New oral anticoagulants: a practical guide for clinicians. J Thromb Thrombolysis 29(2):182–191

    PubMed  Google Scholar 

  155. Pradaxa™ (Dabigatran Etexilate) (2010) Product Information.www.pradaxa.com

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Edith Nutescu.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nutescu, E., Chuatrisorn, I. & Hellenbart, E. Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. J Thromb Thrombolysis 31, 326–343 (2011). https://doi.org/10.1007/s11239-011-0561-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11239-011-0561-1

Keywords

Navigation